Jefferies Financial Group Inc. Has $10.52 Million Stock Position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

Jefferies Financial Group Inc. raised its holdings in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) by 41.1% in the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 305,600 shares of the company’s stock after acquiring an additional 89,000 shares during the quarter. Jefferies Financial Group Inc. owned approximately 0.54% of Harmony Biosciences worth $10,516,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Hillsdale Investment Management Inc. increased its position in Harmony Biosciences by 0.4% in the 4th quarter. Hillsdale Investment Management Inc. now owns 68,000 shares of the company’s stock valued at $2,340,000 after acquiring an additional 300 shares during the period. O Shaughnessy Asset Management LLC boosted its stake in shares of Harmony Biosciences by 2.1% in the 4th quarter. O Shaughnessy Asset Management LLC now owns 20,450 shares of the company’s stock valued at $704,000 after purchasing an additional 420 shares during the last quarter. GAMMA Investing LLC boosted its stake in shares of Harmony Biosciences by 92.6% in the 4th quarter. GAMMA Investing LLC now owns 907 shares of the company’s stock valued at $31,000 after purchasing an additional 436 shares during the last quarter. PNC Financial Services Group Inc. boosted its stake in shares of Harmony Biosciences by 28.7% in the 4th quarter. PNC Financial Services Group Inc. now owns 2,328 shares of the company’s stock valued at $80,000 after purchasing an additional 519 shares during the last quarter. Finally, Aviva PLC boosted its stake in shares of Harmony Biosciences by 3.9% in the 4th quarter. Aviva PLC now owns 18,072 shares of the company’s stock valued at $622,000 after purchasing an additional 686 shares during the last quarter. 86.23% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts have recently commented on the stock. Needham & Company LLC reaffirmed a “buy” rating and issued a $49.00 price objective on shares of Harmony Biosciences in a research note on Tuesday, May 6th. UBS Group reduced their price objective on shares of Harmony Biosciences from $55.00 to $48.00 and set a “buy” rating on the stock in a research note on Monday, April 28th. HC Wainwright reaffirmed a “buy” rating and issued a $70.00 price objective on shares of Harmony Biosciences in a research note on Tuesday, April 8th. Deutsche Bank Aktiengesellschaft assumed coverage on shares of Harmony Biosciences in a research note on Tuesday, February 11th. They issued a “buy” rating and a $55.00 price objective on the stock. Finally, Mizuho upped their price objective on shares of Harmony Biosciences from $42.00 to $44.00 and gave the company an “outperform” rating in a research note on Tuesday, March 18th. Nine equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $52.33.

Harmony Biosciences Trading Down 0.1%

NASDAQ:HRMY opened at $34.05 on Monday. The company has a current ratio of 3.24, a quick ratio of 3.20 and a debt-to-equity ratio of 0.28. The stock has a market capitalization of $1.96 billion, a price-to-earnings ratio of 16.14, a PEG ratio of 0.47 and a beta of 0.82. The firm has a fifty day simple moving average of $31.38 and a two-hundred day simple moving average of $34.01. Harmony Biosciences Holdings, Inc. has a 12 month low of $26.47 and a 12 month high of $41.61.

Harmony Biosciences (NASDAQ:HRMY) last posted its quarterly earnings results on Tuesday, May 6th. The company reported $0.78 EPS for the quarter, topping analysts’ consensus estimates of $0.59 by $0.19. The business had revenue of $184.73 million during the quarter, compared to analysts’ expectations of $184.26 million. Harmony Biosciences had a net margin of 17.98% and a return on equity of 23.16%. The business’s quarterly revenue was up 19.5% on a year-over-year basis. During the same period last year, the company posted $0.67 earnings per share. Analysts expect that Harmony Biosciences Holdings, Inc. will post 2.43 EPS for the current fiscal year.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.